Índice

• • ·Biology-driven medicine: tissue matters

    Página :319

     
• • ·Aromatase inhibitors in premenopausal breast cancer

    Página :320-321

    Catherine M Kelly, Aman U Buzdar

     
• • ·Primary care and diagnosis of cancer

    Página :321-323

    Martin Gulliford

     
• • ·Permissive mismatches for blood and marrow transplantation

    Página :323-324

    Paul Szabolcs

     
• • ·Inflammatory HER2-positive breast cancer

    Página :324-326

    Luc Y Dirix, Peter B Vermeulen

     
• • ·Link between endometriosis and ovarian-cancer subtypes

    Página :326-328

    Charlie Gourley

     
• • ·SBRT and spinal metastasis: finding its niche

    Página :328-329

    David Schiff, Jason P Sheehan

     
• • ·Anti-CD22 therapy in acute lymphoblastic leukaemia

    Página :329-331

    Dieter Hoelzer

     
• • ·Long-term outcome of breast conserving therapy

    Página :331-333

    John R Benson

     
• • ·Aromatase inhibitors and musculoskeletal adverse events

    Página :333-334

    Pedro ER Liedke, Paul E Goss

     
• • ·Standardisation of clinical breast-density measurement

    Página :334-336

    Kwan-Hoong Ng, Cheng-Har Yip, Nur Aishah Mohd Taib

     
• • ·Erratum

    Página :e134

     
• • ·Erratum

    Página :e135

    
• • ·Absent benefit of accelerated concomitant chemoradiotherapy

    Página :e136

    Robin J Prestwich, Mehmet Sen

    
• • ·Absent benefit of accelerated concomitant chemoradiotherapy – Authors’ reply

    Página :e136

    Jean Bourhis, Yun Gan Tao, Pierre Blanchard, Christian Sire, Anne Aupérin

     
• • ·Screening of symptomatic women for ovarian cancer

    Página :e137

    Christopher P Crum

    
• • ·Screening of symptomatic women for ovarian cancer

    Página :e137

    Alicia A Tone, David G Huntsman, Dianne M Miller

     
• • ·Screening of symptomatic women for ovarian cancer

    Página :e138

    Aleksandra Gentry-Maharaj, Jatinderpal Kalsi, Matthew Burnell, Ranjit Manchanda, Usha Menon

    
• • ·Screening of symptomatic women for ovarian cancer – Authors’ reply

    Página :e139

    Lucy Gilbert, Olga Basso, for the DOvE Study Group

    
• • ·Second-line erlotinib for non-small-cell lung cancer

    Página :e141

    Vito Lorusso, Saverio Cinieri

     
• • ·Second-line erlotinib for non-small-cell lung cancer – Authors’ reply

    Página :e142

    Tudor Ciuleanu

    
• • ·Industry group “threatens” journals to delay publications

    Página :337

    Bryant Furlow

     
• • ·Unrest in Bulgarian health services

    Página :338

    Talha Khan Burki

     
• • ·Carcinogenicity of malaria and of some polyomaviruses

    Página :339-340

    Véronique Bouvard, Robert A Baan, Yann Grosse, Béatrice Lauby-Secretan, Fatiha El Ghissassi, Lamia Benbrahim-Tallaa, Neela Guha, Kurt Straif, on behalf of the WHO International Agency for Research on Cancer Monograph Working Group

     
• • ·BRCA1 testing for triple-negative breast cancer

    Página :e143

    Neil Bennet

     
• • ·Semuloparin for thromboprophylaxis during chemotherapy

    Página :e143

    Tim Dehnel

    
• • ·Cancer risk and juvenile idiopathic arthritis

    Página :e144

    Olaya Astudillo

     
• • ·Study shows how NSAIDs inhibit lymphatic metastasis

    Página :e144

    Neil Bennet

    
• • ·Cancer drugs not approved for Australian Government subsidies

    Página :e145

    Georgina Kenyon

     
• • ·US judge strikes down graphic tobacco warnings

    Página :e145

    Bryant Furlow

    
• • ·Cola colourant carcinogenicity claims

    Página :e146

    Bryant Furlow

     
• • ·Indian government awards compulsory licence for sorafenib

    Página :e146

    Talha Khan Burki

    
• • ·End of the road for red meat?

    Página :e147

    Talha Khan Burki

     
• • ·Encouraging results for imatinib in advanced chordoma

    Página :e147

    Kathryn Senior

    
• • ·Wit

    Página :341

    Aaron van Dorn

     
• • ·Crowding out cancer

    Página :342

    Mario Christodoulou

     
• • ·Pink Ribbons, Inc

    Página :343

    Talha Khan Burki

     
• • ·Semper Fi: Always Faithful

    Página :344

    Talha Khan Burki

     
• • ·Voices from the front: April

    Página :344

    David M Mastrianni

    
• • ·Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial

    Página :345-352

    Norikazu Masuda, Yasuaki Sagara, Takayuki Kinoshita, Hiroji Iwata, Seigo Nakamura, Yasuhiro Yanagita, Reiki Nishimura, Hirotaka Iwase, Shunji Kamigaki, Hiroyuki Takei, Shinzaburo Noguchi

    Resumen Resumen Esquema Esquema   
• • ·Variation in number of general practitioner consultations before hospital referral for cancer: findings from the 2010 National Cancer Patient Experience Survey in England

    Página :353-365

    Georgios Lyratzopoulos, Richard D Neal, Josephine M Barbiere, Gregory P Rubin, Gary A Abel

    Resumen Resumen Esquema Esquema   
• • ·Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study

    Página :366-374

    Katharina Fleischhauer, Bronwen E Shaw, Theodore Gooley, Mari Malkki, Peter Bardy, Jean-Denis Bignon, Valérie Dubois, Mary M Horowitz, J Alejandro Madrigal, Yasuo Morishima, Machteld Oudshoorn, Olle Ringden, Stephen Spellman, Andrea Velardi, Elisabetta Zino, Effie W Petersdorf, on behalf of the International Histocompatibility Working Group in Hematopoietic Cell Transplantation

    Resumen Resumen Esquema Esquema   
• • ·Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study

    Página :375-384

    Jean-Yves Pierga, Thierry Petit, Thierry Delozier, Jean-Marc Ferrero, Mario Campone, Joseph Gligorov, Florence Lerebours, Henri Roché, Thomas Bachelot, Emmanuelle Charafe-Jauffret, Maria Pavlyuk, Sandrine Kraemer, François-Clément Bidard, Patrice Viens

    Resumen Resumen Esquema Esquema  
• • ·Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies

    Página :385-394

    Celeste Leigh Pearce, Claire Templeman, Mary Anne Rossing, Alice Lee, Aimee M Near, Penelope M Webb, Christina M Nagle, Jennifer A Doherty, Kara L Cushing-Haugen, Kristine G Wicklund, Jenny Chang-Claude, Rebecca Hein, Galina Lurie, Lynne R Wilkens, Michael E Carney, Marc T Goodman, Kirsten Moysich, Susanne K Kjaer, Estrid Hogdall, Allan Jensen, Ellen L Goode, Brooke L Fridley, Melissa C Larson, Joellen M Schildkraut, Rachel T Palmieri, Daniel W Cramer, Kathryn L Terry, Allison F Vitonis, Linda J Titus, Argyrios Ziogas, Wendy Brewster, Hoda Anton-Culver, Alexandra Gentry-Maharaj, Susan J Ramus, A Rebecca Anderson, Doerthe Brueggmann, Peter A Fasching, Simon A Gayther, David G Huntsman, Usha Menon, Roberta B Ness, Malcolm C Pike, Harvey Risch, Anna H Wu, Andrew Berchuck, on behalf of the Ovarian Cancer Association Consortium

    Resumen Resumen Esquema Esquema   
• • ·Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1–2 trial

    Página :395-402

    Xin Shelley Wang, Laurence D Rhines, Almon S Shiu, James N Yang, Ugur Selek, Ibrahima Gning, Ping Liu, Pamela K Allen, Syed S Azeem, Paul D Brown, Hadley J Sharp, David C Weksberg, Charles S Cleeland, Eric L Chang

    Resumen Resumen Esquema Esquema  
• • ·Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

    Página :403-411

    Hagop Kantarjian, Deborah Thomas, Jeffrey Jorgensen, Elias Jabbour, Partow Kebriaei, Michael Rytting, Sergernne York, Farhad Ravandi, Monica Kwari, Stefan Faderl, Mary Beth Rios, Jorge Cortes, Luis Fayad, Robert Tarnai, Sa A Wang, Richard Champlin, Anjali Advani, Susan O’Brien

    Resumen Resumen Esquema Esquema   
• • ·Breast conserving therapy versus mastectomy for stage I–II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial

    Página :412-419

    Saskia Litière, Gustavo Werutsky, Ian S Fentiman, Emiel Rutgers, Marie-Rose Christiaens, Erik Van Limbergen, Margreet HA Baaijens, Jan Bogaerts, Harry Bartelink

    Resumen Resumen Esquema Esquema   
• • ·Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2–3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study

    Página :420-432

    J Sven D Mieog, James P Morden, Judith M Bliss, R Charles Coombes, Cornelis JH van de Velde, on behalf of the IES Steering Committee

    Resumen Resumen Esquema Esquema   
• • ·Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA)

    Página :e148

    Laura Biganzoli, Hans Wildiers, Catherine Oakman, Lorenza Marotti, Sibylle Loibl, Ian Kunkler, Malcolm Reed, Stefano Ciatto, Adri C Voogd, Etienne Brain, Bruno Cutuli, Catherine Terret, Margot Gosney, Matti Aapro, Riccardo Audisio

    Resumen Resumen Esquema Esquema
• • ·Tattoos, inks, and cancer

    Página :e161

    Nicolas Kluger, Virve Koljonen

    Resumen Resumen Esquema Esquema
• • ·Evaluation of novel radiotherapy technologies: what evidence is needed to assess their clinical and cost effectiveness, and how should we get it?

    Página :e169

    Judith van Loon, Janneke Grutters, Fergus Macbeth

    Resumen Resumen Esquema Esquema  
• • ·Genetic heterogeneity and cancer drug resistance

    Página :e178

    Nicholas C Turner, Jorge S Reis-Filho

    Resumen Resumen Esquema Esquema